Patents Assigned to KalVista Pharmaceuticals Limited
  • Polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof
    Patent number: 11739068
    Abstract: The invention provides new polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3 -(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: October 20, 2021
    Date of Patent: August 29, 2023
    Assignee: KalVista Pharmaceuticals Limited
    Inventors: Haydn Beaton, David Malcolm Crowe, Hannah Joy Edwards
  • Enzyme inhibitors
    Patent number: 11613527
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: March 28, 2023
    Assignee: KalVista Pharmaceuticals Limited
    Inventors: Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson, Alessandro Mazzacani, Michael John Stocks, Thomas Matthew Baker, Matthew Robert Conroy, Alun John Smith, David Edward Clark
  • Solid forms of a plasma kallikrein inhibitor and salts thereof
    Patent number: 11584735
    Abstract: New solid forms of the plasma kallikrein inhibitor, 1-({4-[(5-fluoro-2-oxopyridin-1-yl)methyl]phenyl}methyl)-N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide and its salts, are described.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: February 21, 2023
    Assignee: KalVista Pharmaceuticals Limited
    Inventors: David Malcolm Crowe, Edwin Aret, Kiran Gandhi, Ruben Henricus Carolus Adrianus Titus Lelieveld, Emma Kay Sharp, Richard Simon Todd
  • Inhibitors of plasma kallikrein
    Patent number: 11242333
    Abstract: The present invention provides compounds of formula (I), compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, R12, R13, A, L, B, n, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: February 8, 2022
    Assignee: Kalvista Pharmaceuticals Limited
    Inventors: Hannah Joy Edwards, David Michael Evans, Premji Meghani, Andrew Richard Novak
  • Dosage forms comprising a plasma kallikrein inhibitor
    Patent number: 11234939
    Abstract: The present invention relates to oral solid dosage forms comprising a plasma kallikrein inhibitor, in particular a solid form (Form 1) of the compound of Formula A. Also provided are methods of preparing oral solid dosage forms comprising the compound of Formula A using Form 1 of the compound of Formula A.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: February 1, 2022
    Assignee: KalVista Pharmaceuticals Limited
    Inventors: John Herman Collett, Gary Paul Cook, Jamie Joseph Farrar, Michael John Frodsham, Michael Bryan Roe, Richard Simon Todd, Robert Neil Ward
  • Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors
    Patent number: 11230537
    Abstract: The invention provides new polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof, pharmaceutical compositions containing them and their use as kallikrein inhibitors in therapy.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: January 25, 2022
    Assignee: KalVista Pharmaceuticals Limited
    Inventors: Haydn Beaton, David Malcolm Crowe, Hannah Joy Edwards, Nicholas James Griffiths-Haynes
  • N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors
    Patent number: 11198691
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: December 14, 2021
    Assignee: KalVista Pharmaceuticals Limited
    Inventors: Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson
  • Pyrazole derivatives as plasma kallikrein inhibitors
    Patent number: 11180484
    Abstract: The present invention provides a selection of compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: November 23, 2021
    Assignee: KalVista Pharmaceuticals Limited
    Inventors: Rebecca Louise Davie, Hanna Joy Edwards, David Michael Evans, Simon Teanby Hodgson, Stephen John Pethen, David Philip Rooker
  • N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors
    Patent number: 11084809
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: August 10, 2021
    Assignee: KalVista Pharmaceuticals Limited
    Inventors: Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson
  • N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
    Patent number: 11001578
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: May 11, 2021
    Assignee: KALVISTA PHARMACEUTICALS LIMITED
    Inventors: Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson
  • N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
    Patent number: 10781181
    Abstract: The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, U, D, E, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: November 26, 2015
    Date of Patent: September 22, 2020
    Assignee: KALVISTA PHARMACEUTICALS LIMITED
    Inventors: David Michael Evans, Rebecca Louise Davie, Hannah Joy Edwards, Simon Teanby Hodgson
  • Polymorphs of N-[(6-cyano-2-fluoro)-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide as kallikrein inhibitors
    Patent number: 10752607
    Abstract: The invention provides new polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: August 25, 2020
    Assignee: KALVISTA PHARMACEUTICALS LIMITED
    Inventors: Haydn Beaton, Jonathan Yates Boxhall, David Malcolm Crowe
  • N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors
    Patent number: 10611758
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: April 7, 2020
    Assignee: Kalvista Pharmaceuticals Limited
    Inventors: Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson
  • Pharmaceutical compositions
    Patent number: 10478409
    Abstract: The invention relates to aqueous suspension pharmaceutical compositions of poorly water soluble drugs, wherein said drugs are selected from compounds of formula I wherein R1-R9 are defined herein; processes for preparing these compositions and their use in medicine, especially their use in the treatment of ocular diseases.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: November 19, 2019
    Assignee: Kalvista Pharmaceuticals Limited
    Inventors: Gary Paul Cook, Garry Thomas Gwozdz, Theodore Patrick Laslo
  • N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
    Patent number: 10364238
    Abstract: The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: November 26, 2015
    Date of Patent: July 30, 2019
    Assignee: Kalvista Pharmaceuticals Limited
    Inventors: Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson
  • Inhibitors of plasma kallikrein
    Patent number: 10221161
    Abstract: The present invention provides compounds of formula (I), compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, R12, R13, A, L, B, n, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: March 5, 2019
    Assignee: Kalvista Pharmaceuticals Limited
    Inventors: Hannah Joy Edwards, David Michael Evans, Premji Meghani, Andrew Richard Novak
  • Pharmaceutical compositions suitable for parenteral administration comprising aqueous suspensions of benzylamine derivatives having low solubilities
    Patent number: 9849100
    Abstract: The invention relates to aqueous suspension pharmaceutical compositions of poorly water soluble drugs, wherein said drugs are selected from compounds of formula (I) (Formula (I)), wherein R1-R9 are defined herein; processes for preparing these compositions and their use in medicine, especially their use in the treatment of ocular diseases.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: December 26, 2017
    Assignee: Kalvista Pharmaceuticals Limited
    Inventors: Gary Paul Cook, Garry Thomas Gwozdz, Theodore Patrick Laslo
  • Bicyclic inhibitors
    Patent number: 9738641
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein A, B, W, X and Y are as defined herein.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: August 22, 2017
    Assignee: Kalvista Pharmaceuticals Limited
    Inventors: Hannah Joy Edwards, David Michael Evans, Rebecca Louise Davie, David Philip Rooker, Steven John Hewison
  • Benzylamine derivatives
    Patent number: 9670157
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R3, R5 to R9, A, P, V, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: June 6, 2017
    Assignee: Kalvista Pharmaceuticals Limited
    Inventors: Christine Elizabeth Allan, Andrzej Roman Batt, Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Stephen John Pethen
  • Heterocyclic derivates
    Patent number: 9533987
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: January 3, 2017
    Assignee: Kalvista Pharmaceuticals Limited
    Inventors: Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson, Iain Miller, Andrew Richard Novak, Alun John Smith, Michael John Stocks